GPRC5D and Miyoshi myopathy: Several trials have examined the safety, tolerability, and efficacy of GPRC5D-targeted CAR-T treatment in r/r MM patients (ChiCTR2100048888, 33 patients; NCT04555551, 17 patients; NCT05016778, 10 patients; NCT04674813, 17 patients).